Pfizer Inc. (NYSE:PFE) Position Increased by Howard Financial Services LTD.

Howard Financial Services LTD. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,554 shares of the biopharmaceutical company’s stock after purchasing an additional 495 shares during the period. Howard Financial Services LTD.’s holdings in Pfizer were worth $348,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its holdings in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after acquiring an additional 11,099,024 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after acquiring an additional 8,473,686 shares during the period. Morgan Stanley boosted its holdings in shares of Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after acquiring an additional 348,628 shares during the period. Norges Bank acquired a new position in shares of Pfizer during the fourth quarter valued at $2,129,927,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Pfizer by 13.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after acquiring an additional 8,298,920 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on PFE shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Trading Up 0.6 %

NYSE PFE traded up $0.18 on Friday, hitting $27.98. 32,007,141 shares of the company were exchanged, compared to its average volume of 40,899,391. The company’s 50 day moving average price is $27.81 and its 200-day moving average price is $27.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The firm has a market capitalization of $158.55 billion, a P/E ratio of -467.09, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.23 EPS. Analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.